Verition Fund Management LLC Has $2.91 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Verition Fund Management LLC lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,000 shares of the company’s stock after selling 1,989 shares during the quarter. Verition Fund Management LLC’s holdings in Krystal Biotech were worth $2,912,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Krystal Biotech by 3.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock valued at $840,000 after buying an additional 153 shares in the last quarter. Blueshift Asset Management LLC bought a new position in Krystal Biotech in the 3rd quarter valued at $332,000. BNP Paribas Financial Markets raised its position in Krystal Biotech by 346.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,433 shares of the company’s stock valued at $1,899,000 after purchasing an additional 8,098 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new position in Krystal Biotech in the 3rd quarter valued at $417,000. Finally, Summit Trail Advisors LLC bought a new position in Krystal Biotech in the 3rd quarter valued at $1,893,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.10% of the company’s stock.

Krystal Biotech Trading Up 0.9 %

NASDAQ KRYS opened at $187.62 on Thursday. The stock has a 50-day simple moving average of $181.08 and a 200 day simple moving average of $184.29. The company has a market capitalization of $5.40 billion, a PE ratio of 106.00 and a beta of 0.80. Krystal Biotech, Inc. has a 12 month low of $100.98 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same period in the previous year, the firm earned ($0.67) earnings per share. The company’s revenue was up 879.9% on a year-over-year basis. As a group, sell-side analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on KRYS shares. Evercore ISI lifted their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Stifel Nicolaus boosted their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $202.29.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).